Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reactive Oxygen Species

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Reactive Oxygen Species. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-009036-77 Sponsor Protocol Number: PARIBU - 024 Start Date*: Information not available in EudraCT
    Sponsor Name:Section of dental pharmacology and pharmacotherapy, ICO, University of Oslo
    Full Title: THE EFFECT OF IBUPROFEN AND PARACETAMOL ON REACTIVE OXYGEN SPECIES (ROS) IN LEUKOCYTES.
    Medical condition: Radical oxygen activity in leukocytes.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003962-10 Sponsor Protocol Number: DOA_HO Start Date*: 2015-12-10
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of Hyperoxia on Haemostasis, Inflammation and oxidative Stress
    Medical condition: Effects of hyperoxia on haemostasis, inflammation and reactive oxygen species
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004406-10 Sponsor Protocol Number: 000 Start Date*: 2013-10-09
    Sponsor Name:University Hospital Hradec Kralove
    Full Title: The use of oxygen and hydrogen mixture for inhalation to prevent ischaemia-reperfusion injury
    Medical condition: The patients suffering form acute transmural myocardial infarction and treated with percutaneous transluminal coronary angioplasty will be included in the study. After the recanalisation of occlude...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013228-21 Sponsor Protocol Number: Start Date*: 2010-07-06
    Sponsor Name:University of Oxford
    Full Title: Prevention of atrial oxidative stress and electrical remodelling in patients undergoing cardiac surgery: randomised placebo-controlled trial of perioperative high-dose atorvastatin
    Medical condition: POST-OPERATIVE ATRIAL FIBRILLATION
    Disease: Version SOC Term Classification Code Term Level
    13 10003658 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001584-36 Sponsor Protocol Number: 2014-03-11 Start Date*: 2016-06-01
    Sponsor Name:Universitetssjukhuset Örebro
    Full Title: Is high oxygen concentration a riskfactor for postoperative complications? A prospective, randomized, singel blinded study in elderly patients undergoing vascular surgery
    Medical condition: Elective vascular surgery (peripheral vascular and aortic surgery)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003680-38 Sponsor Protocol Number: HDVitC Start Date*: 2015-06-12
    Sponsor Name:VU university medical center
    Full Title: Pharmacokinetics of two different high dose regimes of intravenous vitamin C in critically ill patients
    Medical condition: Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of ad...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016738-28 Sponsor Protocol Number: ALISEI Start Date*: 2009-12-11
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015488 Essential hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001971-61 Sponsor Protocol Number: SALYCENDO Start Date*: 2016-08-29
    Sponsor Name:Radboudumc
    Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia.
    Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003296-60 Sponsor Protocol Number: Oxidise Start Date*: 2018-04-09
    Sponsor Name:University Hospital Tuebingen
    Full Title: Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study
    Medical condition: Patients with T2DM aged 40 to 70 years (including)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000887-27 Sponsor Protocol Number: 1.0 Start Date*: 2013-05-23
    Sponsor Name:Medizinische Universität Wien
    Full Title: Pilot Trial: The effects of intravenous heme arginate on HO-1 expression and oxidative stress in the human heart
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10055224 Cardiac ischemia LLT
    14.1 100000004849 10023031 Ischemia coronary artery origin LLT
    14.1 100000004849 10023033 Ischemia myocardial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000942-39 Sponsor Protocol Number: NL34476.068.11 Start Date*: 2011-06-20
    Sponsor Name:CTMM, the Center for Translational Molecular Medicine
    Full Title: Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.
    Medical condition: This trial includes overweight patients with both hypothyroidism and type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001342-19 Sponsor Protocol Number: YHGT-CEV-R1 Start Date*: 2020-11-13
    Sponsor Name:Asieris MediTech Co., Ltd.
    Full Title: A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepit...
    Medical condition: Patients with cervical histologic HSIL.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004872 10064455 HSIL LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Ongoing) DE (Completed) SK (Completed) PL (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015600-26 Sponsor Protocol Number: CSPP100ADE05T Start Date*: 2009-12-07
    Sponsor Name:Universitätsklinikum Würzburg
    Full Title: An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients wit...
    Medical condition: Determination of the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hype...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000764-30 Sponsor Protocol Number: HOT-LOCO Start Date*: 2021-07-06
    Sponsor Name:Karolinska University Hospital
    Full Title: Hyperbaric Oxygen for Treatment of Long COVID syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial
    Medical condition: Long COVID, post-acute COVID-19 Syndrome, post COVID-19 Syndrome (ICD-10 U09.0)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.1 10021881 - Infections and infestations 10057244 Post viral fatigue syndrome PT
    20.0 10007541 - Cardiac disorders 10063080 Postural orthostatic tachycardia syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001725-26 Sponsor Protocol Number: X-CGD-Version2 Start Date*: 2013-03-12
    Sponsor Name:Johann Wolfgang Goethe-University
    Full Title: A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector
    Medical condition: Chronic granulomatous disease (CGD) is a congenital immunodeficiency, in which neutrophil granulocytes and monocytes are not capable of producing reactive oxygen species and therefore are unable to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003299-15 Sponsor Protocol Number: METFORAGING Start Date*: 2021-10-19
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz
    Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi...
    Medical condition: Patients with HIV and accelerated biological aging
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004708-20 Sponsor Protocol Number: RIFSYS Start Date*: 2014-03-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients wi...
    Medical condition: Cirrhosis and chronic hepatic encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004871 10024667 Liver cirrhosis LLT
    18.0 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003270-14 Sponsor Protocol Number: POSA-FLU Start Date*: 2017-11-06
    Sponsor Name:UZ Leuven
    Full Title: A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of Posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients
    Medical condition: invasive aspergillosis in critically ill patients with influenza pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000203-89 Sponsor Protocol Number: NeoVanc Start Date*: 2016-07-18
    Sponsor Name:Fondazione PENTA Onlus
    Full Title: Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and inf...
    Medical condition: Neonatal late onset sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10053598 Late onset neonatal sepsis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) EE (Ongoing) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 10:21:51 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA